Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Longmont Dental Loft Announces Chief Calming Pawfficer is Returning


dog sitting on a patients lap

Bentley with a patient

He’s been extremely popular with our patients. In fact, in the past year we’ve had 3 patients adopt Australian Labradoodles as a result of meeting Bentley

After a hiatus due to COVID-19, Longmont Dental Loft’s therapy dog will be returning to the office effective June 29th, 2020. Bentley is an Australian Labradoodle with the title of Chief Calming Pawfficer. As the Chief Calming Pawfficer, Bentley interacts with patients that enjoy being around dogs. He typically sits on patients laps and is a comforting presence that makes patients feel at ease.

“Since we’ve been back from the COVID-19 closure, patients have asked us on a daily basis when Bentley is coming back,” said Adrienne Hedrick, Longmont Dental Loft Dentist, and owner. “He’s been extremely popular with our patients. In fact, in the past year we’ve had 3 patients adopt Australian Labradoodles as a result of meeting Bentley.”

During the past few months Bentley has been staying at home. He has had a lot of fun and has kept entertained by taking walks and playing with the vacuum cleaner. However, he misses seeing patients and is ready to go back to the office.

There will be several precautionary measures in place when Bentley is at the office. First, he will be in the office area away from patients unless a patient requests to see him. Second, before a patient encounters him, they will need to make sure they wash their hands. And Bentley won’t be at the office every day. If a patient wants to make sure he is available, Longmont Dental Loft is asking patients to request a visit with him in advance.

About Longmont Dental Loft

Longmont Dental Loft is a family friendly dental provider in Longmont, Colorado. Dr. Adrienne Hedrick and her team provide holistic, leading-edge dentistry to Longmont, Colorado residents who seek a trusted dental group with a practical approach that combines state of the art technology with education, efficiency, and genuine care. Services include everything from preventative care to full mouth rehabilitation. For additional information, visit http://www.longmontdentalloft.com

Share article on social media or email:

Mindbloom Launches Remote-Enabled Psychedelic Therapy In California To Meet Growing Demand


Mindbloom, a New York City-based consumer mental health and wellbeing company, has announced it will begin offering remote psychedelic therapy services to residents in the state of California this week. The company currently offers psychiatric clinician-supervised ketamine therapy to treat depression and anxiety to clients in New York, New Jersey, Nevada, Pennsylvania, and Florida with affordable and accessible pricing starting at $150 – $250 per session.

With headquarters on New York City’s Fifth Avenue, Mindbloom lifted its requirement for new clients to begin their journey with an in-person visit in March, converting to a full telehealth model in response to federal mandates for Americans to practice social distancing and limit unnecessary virus exposure.

Said Mindbloom Founder and CEO, Dylan Beynon, “As the COVID-19 pandemic escalates in the U.S., conditions for anxiety and depression have never been higher. Our partner clinicians have felt the call to service in this time of crisis. Our team has worked tirelessly to keep up with the demand for safe, accessible and affordable psychedelic medicine treatments.”

Using Mindbloom’s online platform, clients receive personalized, remotely-facilitated psychedelic therapy programs and ongoing virtual support from licensed psychiatric clinicians and trained guides. From initial video consultations to post-treatment 1:1 virtual integration sessions, Mindbloom clients are supported and supervised every step of the way.

How It Works:

  • Following an online survey to assess qualifying symptoms such as anxiety and depression, new clients consult with a licensed psychiatric clinician over video.
  • Ketamine tablets are prescribed and delivered to qualifying clients’ homes.
  • The first therapy session is scheduled; each session requires an in-person peer monitor to be present for the duration of the session.
  • A virtual provider prepares the client and peer monitor ahead of the session and remains available on-demand throughout the session.
  • Audioscapes and personalized psychedelic therapy content is available through Mindbloom’s web-based online platform to enhance the at-home experience.
  • Following each session, virtual providers are available to provide 1:1 integration support.

Said Mindbloom Medical Director Dr. Leonardo Vando, “We are fortunate to be in the position to accelerate the roll-out of our remote ketamine therapy programs in response to one of the greatest public health challenges Americans have ever faced.” He added, “Mindbloom began piloting remote treatment protocols several months prior to the onset of COVID-19, and we’ve safely and successfully facilitated over 500 remote sessions with overwhelmingly positive client outcomes.”

Mindbloom was established to increase Americans’ access to affordable, effective, and science-backed therapeutic experiences designed by leaders in the fields of psychiatry and psychedelic medicine. Founded by tech entrepreneur Dylan Beynon, designed by one of America’s foremost psychedelic medicine experts Dr. Casey Paleos, and clinically overseen by leading psychiatrist Dr. Leonardo Vando, Mindbloom’s initial offering is guided ketamine therapy affordably priced at $150 – $250 per session.

For more information about Mindbloom’s remote treatment options, safety precautions, or how to request a new client consultation, visit http://www.mindbloom.co

About Mindbloom, Inc.

Mindbloom is America’s leading destination for cutting-edge, science-backed approaches to achieving and maintaining optimal mental health and wellbeing through psychedelic medicine. Founded in New York City by seasoned tech entrepreneur Dylan Beynon, Mindbloom brings clinicians, researchers and technologists together to deliver guided ketamine therapy with supportive, thoughtfully designed, hospitality-inspired experiences. Treatment protocols are overseen by Medical Director and board certified psychiatrist Dr. Leonardo Vando and designed by Scientific Director Dr. Casey Paleos, a pioneer in psychedelic research and treatment. Mindbloom’s mission is to transform lives today to transform the world tomorrow by increasing access to transformational treatments that help its clients heal, grow, and expand their human potential.

Press Inquiries:

press@mindbloom.co

Share article on social media or email:

Valley-Wide Health has chosen WellRyde to improve quality of ridership across its multi-county service area throughout Southern Colorado


WellRyde

WellRyde

“We are excited to start our new transportation service with the tools offered by WellRyde software platform. WellRyde will offer our team the ability to effectively communicate, be efficient with our resources, and meet the needs of our clients and patients”, Jania Arnoldi, President/CEO, VWHS.

nuVizz Inc., today announced that Valley-Wide Health Systems, a Community / Migrant Health Center has chosen WellRyde to help facilitate trips across its network. Valley-Wide has thirteen primary healthcare delivery sites strategically located throughout multiple rural counties in Southern Colorado. These full-service clinics are complemented by eight dental clinics, four physical therapy clinics and numerous ancillary health services to address routine and/or complex needs of the patient population. Valley-Wide is offering this ride program to the patient populations and communities they serve to help them with their appointments, treatments, groceries, and other needs.

With this engagement, Valley-Wide will be able to provide high-quality, safe and integrated care services to the community. The WellRyde platform will enable call center personnel to book ride requests from the riders, provide robust scheduling and dispatch capability to the Transportation team, monitor progress of trips throughout the day and enable drivers to complete these Trips via a user-friendly App.

“We are honored to partner with Valley-Wide Health and enable them to provide quality care to their patient population and community they serve. With WellRyde platform, Valley-Wide can efficiently manage the trips for their riders, enable them to effectively utilize their fleet or drivers, monitor fleet real-time and expand to all locations fairly quickly”, said Veda Ramachandran, Vice President, Customer Success. “WellRyde features will also enable Valley-Wide to provide rich rider experience via reminder calls and SMS alerts thereby ensuring that they do not miss their appointments”.

According to Valley-Wide Health Systems President and CEO, Jania Arnoldi, “We are excited to start our new transportation service with the tools offered by the WellRyde software platform. WellRyde will offer our team the ability to effectively communicate, be efficient with our resources, and meet the needs of our clients and patients”.    

About VWHS

Valley-Wide Health Systems, a Community/Migrant Health Center (C/MHC), is a private non-profit 501 (c)(3) corporation governed by a volunteer community board. Established in 1976, Valley-Wide has thirteen primary health care delivery sites strategically located throughout multiple rural counties in Southern Colorado. These full-service clinics are complemented by eight dental clinics, four physical therapy clinics, and numerous ancillary health services to address routine and/or complex needs of the patient populations and communities served. Valley-Wide serves all ages through a family practice focus approach. Emphasis is placed on assisting the patient, reducing barriers such as cost, culture, language, literacy, and transportation that may hinder use of appropriate health care services.

About nuVizz, Inc.

nuVizz, Inc. (http://www.nuvizz.com) is a leading network-based last mile delivery & transportation management and customer experience SaaS platform.

WellRyde, a nuVizz Transportation solution, is an award-winning network-based delivery & transportation platform. Our mission is to provide a human transportation cloud by leveraging technologies, transportation fleet and rider demand into a common platform. WellRyde provides solutions in the NEMT transportation, K-12, rural transit and demand response. Since its inception in 2015, as a specialized people movement platform, WellRyde has consistently focused on ease of use, ease of deployment, rider engagement and visibility. Combined with its capability of package movement, inherited from nuDeliverIt, WellRyde today is capable of delivering care solutions such as prescription delivery, hospital/clinic supply, nurse visits, day care center visits under the broad umbrella of Non-Emergency Medical Services (NEMS). The HIPAA-compliant platform built on next gen micro-services architecture is poised for rapid growth and expansion and can support over 100 million trips a year. For more information on WellRyde please visit https://www.wellryde.com.

nuVizz Marketplace helps consolidate delivery & transportation demand and supply to create new opportunities for shippers/trip sources and carriers/transportation providers. nuVizz MarketPlace is a transportation network wide program and comes close on the heels of TripMarket that today boasts of nearly 2 million trips a year.

The nuVizz platform hosts more than 2000 companies, 35000+ drivers and supported more than 50 million transactions in 2019 on its SaaS platform. For more information, please visit http://www.nuvizz.com, http://www.nudeliverit.com, http://www.wellryde.com.

Contact: Veda Ramachandran

Vice President, Customer Success

veda@wellryde.com

sales@nuvizz.com

info@wellryde.com

Share article on social media or email:

eClinical Solutions Teams with Karyopharm for COVID-19 Treatment Trial


“The eClinical Solutions team is extremely motivated by the opportunity to contribute to finding new therapies that may treat COVID-19,” said Raj Indupuri, CEO of eClinical Solutions. “We are proud to partner with Karyopharm to support rapid data collection, cleaning and review for this program.”

eClinical Solutions LLC, a leading global provider of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI) on randomized clinical trials for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first study of an XPO1 inhibitor in patients with severe viral infections. XPO1 inhibitors like selinexor (marketed as XPOVIO®) have previously shown preclinical activity against respiratory viruses, including SARS-CoV.

“The eClinical Solutions team is extremely motivated by the opportunity to contribute to finding new therapies that may treat COVID-19,” said Raj Indupuri, CEO of eClinical Solutions. “We are proud to partner with Karyopharm to support rapid data collection, cleaning and review for this program. The way they use modern technologies in clinical research to optimize data collection and analysis demonstrates their dedication to innovation not only in scientific research, but throughout the clinical development process.”

The eClinical Solutions Data Services team configured the data capture system for the trial using Medidata Rave EDC and the elluminate Clinical Data Platform for agile data management and review. The Karyopharm and eClinical Solutions teams collaborated closely to build a fully validated data database to collect data from physicians and patients in just 15 days—an accelerated timeline in order to meet the first patient milestone of this critical research initiative. The eClinical Solutions data management team is using elluminate Data Central to support data review activities for the study to ensure data is rapidly cleaned and available for medical and safety review.

“eClinical Solutions has been a valuable partner on other selinexor research programs. Their team’s knowledge of Karyopharm data standards and processes combined with their expertise in data collection platforms and clinical data management practices helped us meet our accelerated timelines for this important new research,” said Kristan Gallitano, SVP Development Operations at Karyopharm Therapeutics.

About eClinical Solutions

eClinical Solutions is a leading global provider of cloud-based enterprise software and software-driven clinical data services. The elluminate® platform provides life sciences companies with greater control of their clinical trial data. elluminate software and data-driven services have been used by more than 100 life sciences companies on more than 1000 trials. eClinical Solutions has worked with Karyopharm since 2015 to tech-enable a simplified data flow and help produce high quality data for more than 10 studies, including 5 database locks that provided the data for the July 2019 FDA approval of Karyopharm’s lead compound XPOVIO® (selinexor). Learn more about eClinical Solutions and Karyopharm in this Case Study. For more information visit eclinicalsol.com.

About Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit http://www.karyopharm.com.

Share article on social media or email:

CQ fluency, Corporate Plus 2020 Inducted by National Minority Supplier Development Council


CQ fluency was inducted as a National Minority Supplier Development Council (NMSDC) official Corporate Plus® member with supporting sponsorship from Anthem. The NMSDC Corporate Plus program is an ‘unprecedented’ program for minority businesses of the ‘highest caliber’, raising the prominence of minority businesses across America. The Corporate Plus program was established to facilitate requests from corporate members to bridge connections with minority suppliers.

CQ fluency is a certified minority-owned business (MBE) by the NMSDC since 2009. President and CEO of CQ fluency, Elisabete Miranda, is a former board member as well as a former MBEIC Committee Co-Chair. As an MBE, CQ fluency is part of a powerful network of minority businesses directly impacting economic growth in the United States.

The Corporate Plus® status acknowledges CQ fluency’s proven capacity to fulfill national contracts and underscores a commitment to diversity by proactively identifying and building relationships with certified small and minority owned businesses. Upon award of membership, Elisabete said, “I can’t begin to tell you how grateful I am that CQ fluency is now part of an elite group of MBEs (less than 100) that help raise the level and perception of minority businesses to national prominence in corporate America, especially now when minority support is so critically important. ” Elisabete continued, “All of us at CQ fluency thank NMSDC for the recognition and Anthem not only for the nomination but also for being such an important client of ours for several years.”

About CQ fluency:

CQ fluency is a language services company that specializes in culturally relevant translations for life science and healthcare in over 170 languages. We translate meaning and feeling of messages to facilitate real connections and true cultural understanding between people who don’t speak the same language. More about CQ fluency can be found on our website at http://www.CQfluency.com.

About NMSDC:

The National Minority Supplier Development Council, Inc. established in 1973, is a vital link between major corporations and minority business enterprises (MBEs). Each year, member corporations have reported billions of dollars spent with Council- certified Minority Business Enterprises. Serving the United States, The Council is one of the 23 regional affiliates of the National Minority Supplier Development Council, Inc. for more information about NMSDC visit http://www.nmsdc.org

Share article on social media or email:

DuPont Achieves Non-GMO Certification for SeaGel®, Reinforces Commitment to Sustainable, Quality Ingredients


News Image

“As consumers become more informed about what goes into their daily supplements, they’re searching for products that are natural, sustainable and non-GMO,” said Michael Baumann, global strategic marketing manager, DuPont Nutrition & Biosciences

Among consumers, the Non-GMO Project Verified seal is the most trusted non-GMO label, providing assurance that the product has completed a rigorous, unbiased evaluation for compliance with the Non-GMO Project Standard. Drug and dietary supplement manufacturers can now turn to DuPont Nutrition & Biosciences to bring that seal to their end-use soft capsule products.

After scrupulous testing of raw material sourcing and manufacturing, SeaGel® CAP101 and SeaGel® CAP203 non-animal soft capsule technologies achieved Non-GMO Project Verified certification, reinforcing DuPont’s commitment to providing safe, sustainable ingredients that meet industry demand.

SeaGel® offers a plant-based alternative to traditional soft capsules. While soft capsules are one of the most common delivery formats for active ingredients, they are traditionally made with gelatin. Naturally derived from seaweed, SeaGel® is animal-free, making it inclusive to vegan, vegetarian, Halal and Kosher diets. Its recent non-GMO designation allows manufacturers incorporating SeaGel® into their formulation to appeal to a wider range of consumers.

“As consumers become more informed about what goes into their daily supplements, they’re searching for products that are natural, sustainable and non-GMO,” said Michael Baumann, global strategic marketing manager, DuPont Nutrition & Biosciences. “Adding the iconic non-GMO butterfly to their end products helps manufacturers and brand owners provide customers with immediate assurance that a product aligns with their lifestyle needs.”

SeaGel® offers manufacturers solutions to a wide range of formulation challenges, and when compared to alternative vegetarian soft capsule technology, it provides superior sealing performance and reduced leakage. Since seaweed has a higher melting point than gelatin, SeaGel® soft capsules are more heat stable, ensuring they will not become sticky or melt together inside capsule bottles. Its adaptability to shape, color and coating—plus easy incorporation into existing gelatin manufacturing operations—allows for a wide range of brand strategies with minimum capital investment.

“The dietary supplement market is growing rapidly, with 4,000 new products introduced each year in the U.S. alone,” said Benjamin Roscoe, application development & innovation manager, DuPont Nutrition & Biosciences. “By consistently evolving alongside our customers, we’re empowering them to differentiate from competitors and meet consumer demand with safe, natural and sustainably sourced ingredients.”

As North America’s only third-party non-GMO verification program, the Non-GMO Project’s verification continues to set the industry standard for non-GMO food, drug and beauty products. To achieve qualification, suppliers must first pass a rigorous product evaluation which includes a review of raw material sources, manufacturing practices and finished products to prevent contamination by genetically modified organisms (GMOs).

In achieving the recent certification, DuPont confirms its commitment to thorough and precise specifications, quality ingredients and sustainable practices, enabling manufacturers and brand owners to be transparent about ingredient sourcing and manufacturing processes. Ultimately this leads to increased consumer satisfaction and trust.

To learn more about SeaGel® and DuPont’s extensive product portfolio, please visit pharma.dupont.com/pharmaceutical-brands/seagel.html

1. https://www.consumerreports.org/cro/2014/10/where-gmos-hide-in-your-food/index.htm

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandbiosciences.com or http://www.biosciences.dupont.com

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at http://www.dupont.com.

# # #

06/24//2020

DuPont™, the DuPont Oval Logo, XIVIA® and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

For further information contact:

Lindsay Torriero                

+1 407 701 2133                

Lindsay.Torriero@dupont.com

Reena Chaudhary

+91 9769820494

Reena.Chaudhary@dupont.com

Share article on social media or email:

Safe Boating Campaign Reminds Boaters to Boat Sober this Fourth of July


Choose to boat sober this Fourth of July.

Choose to boat sober this Fourth of July.

“Operating a boat – or even being a passenger – is incredibly risky while under the influence of alcohol or drugs.” – Peg Phillips, Executive Director, National Safe Boating Council

The Safe Boating Campaign, a worldwide effort focused on responsible boating, reminds boaters to boat sober this Fourth of July. Boating under the influence, or BUI, is the leading contributing factor in recreational boater deaths, according to the U.S. Coast Guard.

“The July 4 holiday is around the corner, and unfortunately has become known for drinking and boating, and deadly accidents,” said Peg Phillips, executive director of the National Safe Boating Council, and lead organization for the Safe Boating Campaign.

“Operating a boat – or even being a passenger – is incredibly risky while under the influence of alcohol or drugs,” continued Phillips. “Drunken passengers can easily fall overboard, swim near the propeller, lean over the side, or stand up in small boats causing the boat to capsize.”

The side effects of alcohol or drug use, such as impaired judgment, reduced balance and poor coordination, are magnified while boating, due to environmental conditions from the sun, wind and boat motion.

“Impairment can be even more dangerous for boaters, since most have less experience and confidence operating a boat than they do driving a car,” said Yvonne Pentz, communications director of the National Safe Boating Council. “Boaters should also always wear a life jacket, similar to wearing a seat belt when you’re in a vehicle.”

The National Association of State Boating Law Administrators, a partner of the Safe Boating Campaign, in collaboration with the U.S. Coast Guard and law enforcement agencies nationwide, is coordinating the annual Operation Dry Water three-day weekend. This heightened BUI awareness and enforcement effort will be held from July 3 to July 5 in every U.S. state and territory.

Since the inception of the Operation Dry Water Campaign in 2009, law enforcement officers have removed 4,095 BUI operators from the nation’s waterways and made contact with over 1.5 million boaters during the annual three-day weekend.

The Safe Boating Campaign is produced under a grant from the Sports Fish Restoration and Boating Trust Fund and administered by the U.S. Coast Guard. For more information and to follow the campaign on social media, please visit https://safeboatingcampaign.com/.

Share article on social media or email:

American College of Lifestyle Medicine Announces Shift of 2020 Annual Conference to a Live Virtual Format to be Held October 22-25


News Image

“Our content will explore how Lifestyle Medicine plays a critical role in strengthening resilience and reducing vulnerabilities.”

The American College of Lifestyle Medicine today announced that its 2020 Lifestyle Medicine Annual Conference, originally scheduled for Nov. 1-4 in Carlsbad, CA, will now be held as a live, virtual event, Thursday through Sunday, October 22-25, 2020.

Conference registration includes 20 hours of both live and recorded Lifestyle Medicine-related presentations, with an option to participate in an additional eight hours of interactive pre- and post-conference workshops. The conference has been approved for AMA PRA Category 1 Credit™.

Registration for the new virtual event, with the theme “Lifestyle Medicine: Health Restored,” is now open. A full agenda and additional details can be found at https://lifestylemedicineconference.org/

“After thoughtful deliberation, and with the utmost concern for the health and safety of all our constituents, our Board unanimously voted for this change,” said ACLM President Dexter Shurney, MD, MBA, MPH, FACLM, dipABLM. “We are excited that, with this change, even more medical professionals and trainees will have the opportunity to be part of this online medical education experience, showcasing the foremost experts in our field, with evidence-based presentations on food and exercise as medicine, to sleep, social connection, and the other pillars of Lifestyle Medicine.”

LM2020 will open with Legends of Lifestyle Medicine and Their Prescription to the World’s Most Pressing Health Crises, featuring Drs. Dean Ornish, Caldwell Esselstyn, T. Colin Campbell and John McDougall, all of whom are previous recipients of ACLM’s Lifetime Achievement Award. Other notable sessions include Dr. Roy Taylor’s presentation, Averting the Looming Global Pandemic of Type 2 Diabetes: Understanding T2D from the DiRECT, Counterpoint and Counterbalance Research Studies, and ACLM President Dexter Shurney leading an expert panel focused on Lifestyle Medicine: A Health Disparities Solution.

“The new dates in October will offer live sessions with the same scientific rigor and educational experience our annual conference attendees have come to expect,” said 2020 Conference Planning Committee Chair Sami Beg, MD, MPA, MPH, FACLM. “The focus of our content will explore how Lifestyle Medicine plays a critical role in strengthening resilience and reducing vulnerabilities. By treating the root cause of chronic disease, we set a solid foundation for restoring health throughout the nation and around the world.”

Conference registration is set at $599 for ACLM Members, $749 for Non-Members. Student registration is $49 for Members and $99 for Non-Members, with an abundance of student and trainee scholarship opportunities.

The American Board of Lifestyle Medicine (ABLM) certification exam, traditionally hosted immediately following the annual conference, will be offered in 2020 as a “take-from-home” exam November 7-8. Attendance at the virtual conference will fulfill the “live” CME prerequisite for the 2020 ABLM exam. The deadline to register on the ABLM website is September 30, 2020.

“This is an unprecedented time, but out of crisis comes opportunity,” Shurney said. “The events of this year have made the field ACLM represents all the more relevant, with the nation and world awakening to the urgent need for Lifestyle Medicine to become the foundation of health care. Health restoration is what our world needs and what Lifestyle Medicine delivers.”

The 2020 conference is presented by The Prospect Fund, a socially responsible investment fund which offers its resources to advance important causes globally.

ABOUT THE AMERICAN COLLEGE OF LIFESTYLE MEDICINE: ACLM is the medical professional society for those dedicated to the advancement and clinical practice of Lifestyle Medicine as the foundation of a transformed and sustainable health care system. Lifestyle Medicine is the use of a whole food, plant-predominant dietary lifestyle, regular physical activity, restorative sleep, stress management, avoidance of risky substances and positive social connection as a primary therapeutic modality for treatment and reversal of chronic disease.

More than a professional association, ACLM is a galvanized force for change. ACLM addresses the need for quality education and certification, supporting its members in their individual practices and in their collective mission to domestically and globally promote Lifestyle Medicine as the first treatment option, as opposed to a first option of treating symptoms and consequences with expensive, ever increasing quantities of pills and procedures. ACLM members are united in their desire to identify and eradicate the root cause of disease. Learn more at http://www.LifestyleMedicine.org.

Share article on social media or email:

Catalent to Discuss Data-Driven Approaches for Small Molecule Drug Development at the Controlled Release Society Annual Meeting


Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that a number of its experts will present at the upcoming Controlled Release Society (CRS) Annual Meeting, which will take place virtually on June 29 – July 2, 2020.

Cornell Stamoran, Ph.D., founder of Catalent’s Applied Drug Delivery Institute, has been invited to chair two sessions during the conference. Dr. Stamoran will moderate a discussion analyzing the industry’s response to the COVID-19 pandemic, and will also chair Plenary Session 2, featuring Katherine High, M.D.

In her presentation, titled “Data-Driven Formulation Approaches for Oral Small Molecule Drugs,” Lisa Caralli, Director, Science & Technology, will examine the role of physicochemical and biopharmaceutical data in guiding early small molecule drug development decisions. Ms. Caralli will explain how to apply the developability classification system (DCS) to guide formulation design, relate physiochemical properties to the impact on solubility and bioavailability, and discuss the importance of physiologically-based pharmacokinetic (PBPK) modeling in ascertaining a molecule’s developability.

During the conference, Catalent will also present the following scientific posters:

  • “Calcium Methylfolate Compatibility Studies in Gelatin Capsules,” presented by Tiago Barros, Senior Analyst, Research & Development
  • “Quantitation of the Crystalline Phase in Milled Prototype Hot Melt Extrudate Indomethacin Formulations by X-ray Powder Diffraction,” presented by Imre Vitez, Principal Scientist, Physical Pharmaceutics Formulations, Research & Development
  • “Evaluation of Ribbon Porosity as an Indicator of Ribbon Properties of Roller Compacted Material,” presented by Priya Batheja, Principal Scientist, Formulations, Research & Development
  • “Fast and Flexible Preparation Strategy of Lipid-Based Formulation of Early Phase Clinical Study,” presented by Benoit Hilbold, Product Development Supervisor, Research & Development

Dr. Stamoran leads Catalent’s strategic planning, market intelligence and government affairs efforts. He also founded and serves as Co-Chair of Catalent’s Applied Drug Delivery Institute (http://www.drugdeliveryinstitute.com). He has spent more than 30 years engaged with the healthcare industry, including more than 25 years in advanced drug and biologic delivery and outsourcing.

Ms. Caralli has over 27 years of industry experience, and in her role at Catalent, works with pharmaceutical companies to identify appropriate development pathways for early development drug candidates. She has previously held roles at Ionis Pharmaceuticals and Amylin Pharmaceuticals, and began her career at the Immune Response Corporation. Ms. Caralli holds a bachelor’s degree in biochemistry from the University of California at Davis, California.

The presentations will be available to view on-demand through the conference platform. To register, please visit https://2020.controlledreleasesociety.org/registration.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

The GHT Companies Reaches $10,000 Mark in Vitamin Fundraising Pledge for Feeding San Diego


News Image

“We offered our wellness community a substantial discount with the promise that their purchases would support the great work being done locally by Feeding San Diego, and we are proud that we have hit this first milestone of $10,000.” Jim Rex, President of The GHT Companies

The GHT Companies, a leading developer and distributor of nutraceutical products based in San Diego County, announced today that it had hit its first fundraising benchmark of $10,000 in its pledge of raising a minimum of $25,000 for Feeding San Diego, a charity whose mission is to connect every person facing hunger with nutritious meals by maximizing food rescue.

“The health-conscious communities of The GHT Companies, and its Vegan Life Nutrition and Vibrant Nutraceuticals product lines not only care about health but also humanity,” said Jim Rex, President of The GHT Companies. “We offered our wellness community a substantial discount with the promise that their purchases would support the great work being done locally by Feeding San Diego, and we are proud that we have hit this first milestone of $10,000.”

In May, The GHT Companies announced special 25% off pricing on 13 vitamin and nutraceutical products popular with health-minded shoppers and 12 of them focused on supporting the immune system. The products included plant-based D3 vitamins in a variety of formats, the UMAC Marine Phytoplankton product line, the specially-formulated Power HI (H = healthy and I = immune), and the new-to-market Pure Vitamin C. All of the above products are found in two of The GHT Companies’ Branded Product Lines: Vegan Life Nutrition and Vibrant Nutraceuticals.

Each sale from the 13 products results in a one-dollar donation, and larger donations are in place per kilogram for raw ingredients used in the manufacturing of nutraceutical products. They include the well-known Vitashine Vegan Vitamin D3 Oil and Vegan Vitamin D3 Powder.

“Feeding San Diego is inspired to see our community giving back and shopping locally to support companies who are actively raising funds for our cause,” said Gavon Morris, Chief Development and Marketing Officer of Feeding San Diego. “The $10,000 raised thus far directly supports children, families, and seniors facing hunger during COVID-19 throughout San Diego County.”

The work isn’t done yet. The GHT Companies fundraising goal was to hit a minimum of $25,000 at the end of the program.

“We believe our community will come through for this great cause, and we will be excited to provide additional funds to Feeding San Diego,” Rex said.

About The GHT Companies

The GHT Companies is one of the most trusted names in the nutritional supplement field since 1996. The group is structured to collaborate with founding scientists to develop their unique ingredient/product discoveries and to deliver industry-leading, high-quality consumer products, and ingredients on a global basis.

The GHT Companies uses its unique business structure of 5 diverse subsidiaries that touch on all facets of the nutraceutical industry in order to provide products and services to customers in the most effective way possible.

Disclaimer: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Information and statements made are for educational purposes and are not intended to replace the advice of your health care professional.

Media Contact:

Marketing Department, request Shanna Denfeld, Vice-President

(760) 542-3000

marketing@theghtcompanies.com

https://www.vibrantnutra.com

https://www.veganlifenutrition.com

Share article on social media or email: